NeuroSAFE Improves Erectile Function After Radical Prostatectomy
By Elana Gotkine HealthDay Reporter
THURSDAY, April 3, 2025 -- Use of the NeuroSAFE technique, a standardized frozen section analysis that enables accurate real-time detection of positive surgical margins during nerve sparing in robot-assisted radical prostatectomy (RARP), improves patient-reported erectile function, according to a study published online March 24 in The Lancet Oncology.
Eoin Dinneen, Ph.D., from University College London, and colleagues examined the effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in a multicenter, randomized phase 3 trial. Patients with a diagnosis of nonmetastatic prostate cancer deemed suitable to undergo RARP with good erectile function and no previous prostate cancer treatment were enrolled and randomly allocated to standard RARP or NeuroSAFE-guided RARP (191 and 190 patients, respectively).
The researchers found that among the 344 patients in whom data were available at 12 months, the scores on the first five items of the International Index of Erectile Function (IIEF-5) were 12.7 and 9.7 in the NeuroSAFE group (173 patients) and standard RARP group (171 patients), respectively. The International Consultation on Incontinence Questionnaire (ICIQ) score was significantly lower in the NeuroSAFE group than the standard RARP group at three months (adjusted mean difference, −1.41). No significant difference in ICIQ score was seen between the groups at six months. The mean score on the IIEF-6 was higher in the NeuroSAFE group than the standard RARP group at 12 months (15.3 versus 11.5). Serious adverse events occurred in 3 percent of patients in both the NeuroSAFE and the standard RARP groups.
"These findings should inform guideline updates and confirm the role of the NeuroSAFE technique as an adjunct to guide nerve-sparing," the authors write.
One author disclosed ties to Intuitive Surgical.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Acupuncture May Alleviate Nocturia in Men Treated for Prostate Cancer
TUESDAY, June 3, 2025 -- Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published online May 29 in JAMA...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.